Holen Sie sich die Stockscreener-App
1.045
1.42%
-0.015
Handel nachbörslich:
1.05
0.005
+0.48%
Indaptus Therapeutics Inc Aktie (INDP) Neueste Nachrichten
Maxim Group Has Lowered Expectations for Indaptus Therapeutics (NASDAQ:INDP) Stock Price - Defense World
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Indaptus Therapeutics Inc (INDP) Quarterly 10-Q Report - Quartzy
Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology - The Manila Times
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting - The Manila Times
Indaptus' Decoy20 Shows Promise: Phase 1 Trial Reports Safe Weekly Dosing in Cancer Study | INDP Stock News - StockTitan
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences - The Manila Times
Indaptus Therapeutics partners with BeiGene for cancer study By Investing.com - Investing.com Canada
Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment - Morningstar
Indaptus Therapeutics partners with BeiGene for cancer study - Investing.com
Indaptus Therapeutics Announces Clinical Supply Agreement - GlobeNewswire
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations - The Manila Times
Indaptus Therapeutics, Inc. Enters into Clinical Supply Agreement with Beigene Switzerland GmbH - Marketscreener.com
Provident Bank's First-Time Home Buyer Survey Reveals That While Homeownership Continues to Be Challenging, Many Americans Are Finding Their Home in Less Than a Year - The Manila Times
Indaptus Therapeutics Initiates Unrestricted Enrollment of - GlobeNewswire
Indaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20 - MSN
Indaptus Therapeutics Founder and Chief Scientific Officer - GlobeNewswire
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Increases By 140.5% - Defense World
Cybin (NYSEAMERICAN:CYBN) Shares Down 4.4% - Defense World
Japan Tobacco Inc. (OTCMKTS:JAPAY) Short Interest Update - Defense World
Sei Investments Co. Has $17.72 Million Position in Teradata Co. (NYSE:TDC) - Defense World
Indaptus Therapeutics (NASDAQ:INDP) Stock Price Down 9.2% - Defense World
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights - Marketscreener.com
Kaskela Law LLC Announces Shareholder Investigation of Integra LifeSciences Holdings Corp. (NASDAQ: IART) and Encourages Long-Term IART Shareholders to Contact the Firm - Business Wire
The Escalator: Imre, Kyverna Therapeutics, The Bloc and more - MM+M Online
StockNews.com Downgrades Independent Bank (NASDAQ:INDB) to Sell - Defense World
Integrated BioPharma (OTCMKTS:INBP) Trading Down 2.2% - Defense World
Indivior PLC REMINDER – INDV Stockholders Should Contact - GlobeNewswire
IBTX stock hits 52-week high at $60.77 amid robust growth - Investing.com
INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit - PR Newswire
Northland Capmk Equities Analysts Cut Earnings Estimates for Indivior PLC (NASDAQ:INDV) - MarketBeat
Holdings of Intelligent Bio Solutions Inc (INBS) are aligned with the stars - SETE News
Upward Trajectory: Intelligent Bio Solutions Inc (INBS) Posts a Gaine, Closing at 2.48 - The Dwinnex
Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Indivior PLC of Class Action Lawsuit and Upcoming DeadlinesINDV - PR Newswire
Financial Health Check: Examining Indivior Plc (INDV)’s Key Ratios - The Dwinnex
Class Action Lawsuit Against Indivior PLC (NASDAQ:INDV) - TipRanks
Ready to Jump After Recent Trade: Indivior Plc (INDV) - SETE News
Indivior PLC Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsINDV - PR Newswire
Intelligent Bio Solutions Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value - GlobeNewswire
Technical analysis of Intelligent Bio Solutions Inc (INBS) stock chart patterns - US Post News
Negative FDA AdCom vote on Ocaliva - The Pharma Letter
The Gross Law Firm Reminds Indivior Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024INDV - PR Newswire
Piper Sandler Reaffirms “Overweight” Rating for Indivior (NASDAQ:INDV) - Defense World
INDV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Indivior PLC Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Indivior PLC (NASDAQ:INDV) Shares Sold by Royal London Asset Management Ltd. - MarketBeat
INVESTOR ALERT: DiCello Levitt LLP Shareholder Class Action - GlobeNewswire
Indivior's (INDV) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Intl Paper Co stock hits 52-week high at $49.25 amid market rally By Investing.com - Investing.com South Africa
In the Green: Indivior Plc (INDV) Closes at 9.62, Up/Down 0.42 from Previous Day - The Dwinnex
INmune Bio stock dips on $13M securities offering - MSN
Indaptus Therapeutics Reports Encouraging New Safety Data - GlobeNewswire
Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses - GlobeNewswire
INDP stock touches 52-week low at $1.55 amid market challenges - Investing.com Canada
Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Intec Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020 - Marketscreener.com
INDP Stock Earnings: Indaptus Therapeutics Beats EPS for Q2 2024 - InvestorPlace
Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - wallstreet:online
Insider Buyers Lose US$41k As Indaptus Therapeutics Sheds US$1.2m - Simply Wall St
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):